Hear the latest on PCSK9 inhibitors, cardiorenal benefits of GLP-1 drugs, and other clinical research in this interview with Katie Berlacher, MD, MS, chair of this year's annual ACC meeting. Related Content: PCSK9 Inhibitors in Diabetes, Tirzepatide's Cardiorenal Effects, Shingles Vaccine, and More From ACC